Prime medicine reports third quarter 2023 financial results and provides business updates

-- presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- shared detailed safety evaluation of lead prime editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile --
PRME Ratings Summary
PRME Quant Ranking